Dr. Reddy's Laboratories

Global Branded Generics Market Worth $535.8 Billion by 2028 - Industry Analysis with Revenue Breakdown by Type, Distribution and Application - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 9, 2021
Health, Pharmaceutical, Dr. Reddy's Laboratories, Viatris, Growth, Prevalence, GlaxoSmithKline, Sanofi, USD, Endo International, CAGR, Lupin Limited, REMS, Application, Market share, Generic drug

The "Global Branded Generics Market Size By Type, By Distribution Channel, By Application, By Geographic Scope And Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Branded Generics Market Size By Type, By Distribution Channel, By Application, By Geographic Scope And Forecast" report has been added to ResearchAndMarkets.com's offering.
  • The Global Branded Generics Market was valued at USD 270.6 Billion in 2020 and is projected to reach USD 535.8 Billion by 2028, growing at a CAGR of 7.73% from 2021 to 2028.
  • The global market is primarily driven by a significant increase in cardiometabolic risk factors among the masses.
  • The increasing prevalence of cancer cases is also playing a major role in the growth of the Branded Generics Market.

Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

Retrieved on: 
Saturday, September 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Health sciences, Health care, Health, NIFTY 50, Pharmaceuticals policy, Dr. Reddy's Laboratories, Pharmacy, Forward-looking statement, Reddy, Pharmaceutical industry in China, Eisai, Cutaneous T cell lymphoma

Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.

Key Points: 
  • Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.
  • In March 2016, Dr. Reddys had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co. Ltd.
    Erez Israeli, Chief Executive Officer, Dr. Reddys, said: Addressing unmet patient needs in oncology remains a prime focus area for us.
  • E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy’s Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market

Retrieved on: 
Tuesday, August 3, 2021
FDA, Pharmaceutical, Health, Drugs, Nonsteroidal anti-inflammatory drugs, Health care, Health, Analgesics, Propionic acids, Antipyretics, Hepatotoxins, Naproxen, Dr. Reddy's Laboratories, Over-the-counter drug, Pain management

The re-launch of Dr. Reddys Naproxen Sodium Tablets, 220 mg (OTC), is an important addition to our Pain/Analgesics portfolio of OTC products, says Marc Kikuchi, CEO, North America Generics, Dr. Reddys Laboratories.

Key Points: 
  • The re-launch of Dr. Reddys Naproxen Sodium Tablets, 220 mg (OTC), is an important addition to our Pain/Analgesics portfolio of OTC products, says Marc Kikuchi, CEO, North America Generics, Dr. Reddys Laboratories.
  • Dr. Reddys OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal anti-inflammatory drug (NSAID) for use as a pain reliever and fever reducer.
  • Dr. Reddys Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to allow consumers a variety of purchasing options.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy's Laboratories Announces Filing of Annual Report on Form 20-F

Retrieved on: 
Thursday, July 1, 2021
Biotechnology, Pharmaceutical, Health, Financial markets, NIFTY 50, States and union territories of India, India, Dr. Reddy's Laboratories, American depositary receipt, Depositary receipt, Reddy, Radar Doppler Multitarget

The Annual Report on Form 20-F is also available on the website of Dr. Reddys, www.drreddys.com .

Key Points: 
  • The Annual Report on Form 20-F is also available on the website of Dr. Reddys, www.drreddys.com .
  • American Depositary Receipts (ADRs) holders may also obtain a hard copy of the Annual Report on Form 20-F at no cost, by sending a written request to the Companys registered office or by sending an e-mail to [email protected] .
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Global Antacids Market Report 2021 Featuring GlaxoSmithKline, Pfizer, Bayer, Dr. Reddy's Laboratories and AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 29, 2021
General Health, Pharmaceutical, Health, Other Health, Companies, Life sciences, Medical specialties, Heartburn, Gastroesophageal reflux disease, Indigestion, Dr. Reddy's Laboratories, AstraZeneca, Pfizer, Antacids

The "Antacids Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antacids Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the antacids market are GlaxoSmithKline plc, Pfizer Inc., Bayer AG, Dr. Reddy's Laboratories Ltd and AstraZeneca PLC.
  • The antacids market consists of sales of antacids which are used to neutralize stomach acid, and treat acid reflux, heartburn and indigestion.
  • Poor lifestyle choices resulting in higher prevalence of acidity is an important driver for the growth of the antacids market.

Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market

Retrieved on: 
Wednesday, May 12, 2021
Health, Pharmaceutical, Chemical compounds, Pharmaceutical companies, Anilides, Ertapenem, Pyrrolidines, Dr. Reddy's Laboratories, Generic drug, Organic compounds

Reddy\xe2\x80\x99s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \xe2\x80\x9cDr.

Key Points: 
  • Reddy\xe2\x80\x99s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \xe2\x80\x9cDr.
  • Reddy\xe2\x80\x99s\xe2\x80\x9d) today announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).\n\xe2\x80\x9cWe are pleased to bring this important product to market at this time,\xe2\x80\x9d says Marc Kikuchi, CEO, North America Generics, Dr. Reddy\xe2\x80\x99s Laboratories.
  • Gland Pharma has an exclusive API supply arrangement for this product and a dedicated manufacturing facility in Hyderabad for Ertapenem Injection.
  • The company assumes no obligation to update any information contained herein.\xe2\x80\x9d\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511006310/en/\n'

United States Generic Drugs Market Report 2021 Featuring Teva Pharmaceutical Industries, Mylan N.V, Sandoz, Endo Pharmaceuticals, Lupin, Dr Reddy's and Sun pharma

Retrieved on: 
Thursday, April 29, 2021
Pharmaceutical companies, Health care, Life sciences, Pharmaceuticals policy, Generic drug, Teva Pharmaceuticals, Mylan, Pharmaceutical industry in India, Lupin Limited, Pharmaceutical industry, Dr. Reddy's Laboratories, Endo International

In the United States, generic drug production has increased because it is cheaper than any branded medicine.

Key Points: 
  • In the United States, generic drug production has increased because it is cheaper than any branded medicine.
  • In the United States, the decline in medicine price works as the biggest catalyst for the generic drug market growth.
  • These generic medicines prices sometimes declined to 85% less than patented drugs; this happens when various generic drug companies target a single patented drug.
  • The publisher has covered companies\' initiatives that sell various generic drugs in the United States.\nCompanies covered in the report are Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited, Dr Reddy\'s and Sun pharma.\n'

Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India

Retrieved on: 
Tuesday, April 13, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Adenoviridae, COVID-19 vaccines, Clinical trials, COVID-19 pandemic in Russia, Science and technology in Russia, Sputnik V COVID-19 vaccine, Vaccination, Dr. Reddy's Laboratories, Articles, Life sciences, Medicine

Phase II / III clinical trials of the vaccine were carried out by Dr. Reddy\xe2\x80\x99s in India.\nDr Reddy\xe2\x80\x99s Laboratories co-chairman and managing director GV Prasad said, \xe2\x80\x9cWe are very pleased to obtain the emergency use authorisation for Sputnik V in India.

Key Points: 
  • Phase II / III clinical trials of the vaccine were carried out by Dr. Reddy\xe2\x80\x99s in India.\nDr Reddy\xe2\x80\x99s Laboratories co-chairman and managing director GV Prasad said, \xe2\x80\x9cWe are very pleased to obtain the emergency use authorisation for Sputnik V in India.
  • With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19.
  • Sputnik V uses two different vectors for the two shots in a course of vaccination.
  • The company assumes no obligation to update any information contained herein.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210412006057/en/\n'

Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market

Retrieved on: 
Wednesday, April 7, 2021
Health, FDA, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Pharmaceutical companies, Dr. Reddy's Laboratories, Health care, Coenzymes, Lactams, Pteridines, Tetrahydrobiopterin, Health, Generic drug

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, a therapeutic equivalent generic version of Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, a therapeutic equivalent generic version of Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration (USFDA).
  • We are pleased to launch this generic version of Sapropterin Dihydrochloride Powder for Oral Solution, illustrating our continued commitment to bring affordable generic medicines to market for patients, says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddys Laboratories.
  • At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease.
  • Dr. Reddys Sapropterin Dihydrochloride Powder for Oral Solution, is available in 100 mg unit dose packets in a 30 count carton.

Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V.

Retrieved on: 
Friday, March 12, 2021
Biotechnology, Pharmaceutical, Health, Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry, Food and Drug Administration, Dr. Reddy's Laboratories, Novartis, Amring Pharmaceuticals Inc., Amzell B.V., SEVER Life Sciences B.V.

Under this agreement Amzell will complete the full clinical development of the product in specific markets and Amring will commercialize the product.

Key Points: 
  • Under this agreement Amzell will complete the full clinical development of the product in specific markets and Amring will commercialize the product.
  • Amring will invest an undisclosed amount in the development through the clinical phase and FDA approval process.
  • This agreement will significantly expand our commercial presence in the USA and several regions globally, stated Daniel Carbery, President and CEO of Amring.
  • Amring Pharmaceuticals is a privately held pharmaceutical company that provides value-driven brands and niche generics to the market.